Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Swiss Cancer Institute
Swiss Cancer Institute
Maia Biotechnology
Duke University
Montefiore Medical Center
Regeneron Pharmaceuticals
Gustave Roussy, Cancer Campus, Grand Paris
Roswell Park Cancer Institute
The Netherlands Cancer Institute
Duke University
Henry Ford Health System
Mayo Clinic
European Organisation for Research and Treatment of Cancer - EORTC
Gruppo Oncologico Italiano di Ricerca Clinica
Regeneron Pharmaceuticals
Emory University
Intergroupe Francophone de Cancerologie Thoracique
Intergroupe Francophone de Cancerologie Thoracique
UNICANCER
Regeneron Pharmaceuticals
Università Vita-Salute San Raffaele
Regeneron Pharmaceuticals
Fundación GECP
Weill Medical College of Cornell University
Genelux Corporation
Regeneron Pharmaceuticals
City of Hope Medical Center
Jules Bordet Institute
Regeneron Pharmaceuticals